Albemarle Corporation

NYSE:ALB Stock Report

Market Cap: US$11.5b

Albemarle Valuation

Is ALB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$215.72
Fair Value
56.4% undervalued intrinsic discount
26
Number of Analysts

Below Fair Value: ALB ($94.05) is trading below our estimate of fair value ($215.72)

Significantly Below Fair Value: ALB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALB?

Key metric: As ALB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALB. This is calculated by dividing ALB's market cap by their current revenue.
What is ALB's PS Ratio?
PS Ratio1.7x
SalesUS$6.50b
Market CapUS$11.46b

Price to Sales Ratio vs Peers

How does ALB's PS Ratio compare to its peers?

The above table shows the PS ratio for ALB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.8x
SQM Sociedad Química y Minera de Chile
2.4x9.9%US$11.5b
ALTM Arcadium Lithium
6.8x18.2%US$6.2b
CE Celanese
0.8x2.0%US$7.9b
EMN Eastman Chemical
1.2x3.4%US$10.8b
ALB Albemarle
1.7x8.3%US$11.5b

Price-To-Sales vs Peers: ALB is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (2.8x).

Price to Sales Ratio vs Industry

How does ALB's PS Ratio compare vs other companies in the US Chemicals Industry?

14 CompaniesPrice / SalesEstimated GrowthMarket Cap
MATV Mativ Holdings
0.3x1.6%US$519.45m
TSE Trinseo
0.04x4.1%US$154.00m
AVD American Vanguard
0.3x4.0%US$146.24m
ALTO Alto Ingredients
0.1x3.1%US$141.80m
No. of Companies14PS01.22.43.64.86+
14 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ALB is expensive based on its Price-To-Sales Ratio (1.7x) compared to the US Chemicals industry average (1.3x).

Price to Sales Ratio vs Fair Ratio

What is ALB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.7x
Fair PS Ratio0.7x

Price-To-Sales vs Fair Ratio: ALB is expensive based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$94.05
US$116.48
+23.8%
28.3%US$225.00US$73.00n/a26
Jan ’26US$86.08
US$117.72
+36.8%
28.4%US$225.00US$73.00n/a26
Dec ’25US$107.70
US$116.41
+8.1%
29.3%US$225.00US$73.00n/a26
Nov ’25US$98.24
US$113.68
+15.7%
31.2%US$225.00US$73.00n/a26
Oct ’25US$94.32
US$111.98
+18.7%
32.4%US$225.00US$73.00n/a26
Sep ’25US$90.25
US$112.29
+24.4%
32.3%US$225.00US$73.00n/a26
Aug ’25US$93.17
US$126.80
+36.1%
27.0%US$225.00US$81.00n/a25
Jul ’25US$97.41
US$148.46
+52.4%
24.9%US$275.00US$81.00n/a24
Jun ’25US$122.59
US$153.44
+25.2%
24.3%US$275.00US$81.00n/a25
May ’25US$119.00
US$152.40
+28.1%
24.1%US$275.00US$81.00n/a27
Apr ’25US$129.18
US$150.03
+16.1%
25.1%US$275.00US$81.00n/a27
Mar ’25US$142.80
US$152.36
+6.7%
26.6%US$300.00US$90.00n/a27
Feb ’25US$116.78
US$162.37
+39.0%
25.2%US$300.00US$90.00n/a27
Jan ’25US$144.48
US$188.34
+30.4%
30.3%US$308.00US$90.00US$86.0827
Dec ’24US$126.16
US$190.80
+51.2%
30.2%US$308.00US$90.00US$107.7027
Nov ’24US$122.96
US$238.29
+93.8%
23.5%US$350.00US$155.00US$98.2426
Oct ’24US$170.04
US$264.67
+55.7%
17.8%US$350.00US$155.00US$94.3224
Sep ’24US$200.26
US$264.69
+32.2%
18.3%US$350.00US$155.00US$90.2525
Aug ’24US$207.99
US$267.48
+28.6%
19.9%US$360.00US$155.00US$93.1725
Jul ’24US$223.09
US$263.19
+18.0%
20.6%US$360.00US$155.00US$97.4125
Jun ’24US$195.54
US$264.95
+35.5%
21.9%US$360.00US$155.00US$122.5924
May ’24US$177.27
US$285.85
+61.3%
25.2%US$498.00US$155.00US$119.0022
Apr ’24US$221.04
US$319.21
+44.4%
19.6%US$498.00US$155.00US$129.1822
Mar ’24US$252.64
US$315.70
+25.0%
19.3%US$498.00US$155.00US$142.8024
Feb ’24US$285.90
US$313.10
+9.5%
19.8%US$497.00US$155.00US$116.7823
Jan ’24US$216.86
US$314.20
+44.9%
19.5%US$461.00US$155.00US$144.4821
Analyst Price Target
Consensus Narrative from 26 Analysts
US$116.48
Fair Value
19.3% undervalued intrinsic discount
26
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 00:52
End of Day Share Price 2025/01/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Albemarle Corporation is covered by 47 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William SeleskyArgus Research Company
Benjamin KalloBaird
Ishan MajumdarBaptista Research